Eli Lilly Partners with Ro to Expand Access to Lower-Cost Zepbound Vials

The collaboration enables patients to obtain affordable weight-loss drug vials through Ro's telehealth platform, simplifying the prescription and delivery process.

• Eli Lilly and telehealth platform Ro have announced a partnership to make single-dose vials of Zepbound, a popular weight-loss medication, more accessible to patients.
• The vials, priced at $399 and $549 per month before insurance depending on dosage, are more affordable than Zepbound's auto-injector pens, which cost around $1,000 per month.
• Patients can now use Ro's platform to receive an online diagnosis, prescription, and home delivery of Zepbound vials, integrating with Lilly's direct-to-consumer service, LillyDirect.
• This move comes as Eli Lilly seeks to address demand for GLP-1 drugs while discouraging the use of compounded versions, which have gained traction during past shortages.
• The partnership reflects a growing trend in the pharmaceutical industry toward direct-to-consumer models aimed at improving access to high-demand medications.

3 Articles

Stat News CNBC Quartz